Beam Therapeutics (BEAM) director receives stock options on 19,676 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Beam Therapeutics Inc. director Mark Fishman received a grant of stock options covering 19,676 shares of common stock. The options have an exercise price of $29.55 per share and were awarded as compensation, not purchased in the open market.

The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual stockholder meeting, as long as Fishman continues serving on the board through that date. The options expire on June 3, 2036, giving him long-term potential ownership if exercised.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Fishman Mark

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,676	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 19,676 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 19,676 options Exercise price: $29.55 per share Underlying shares: 19,676 shares +3 more

6 metrics

Options granted 19,676 options Stock Option (Right to Buy) grant to director

Exercise price $29.55 per share Conversion/exercise price of granted options

Underlying shares 19,676 shares Common stock underlying the option grant

Expiration date June 3, 2036 Option term end date

Shares after transaction 19,676 options Total derivative holdings following grant

Transaction date June 3, 2026 Date of option grant

Key Terms

Stock Option (Right to Buy), exercise price, underlying security, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "29.5500" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: "Common Stock""

expiration date financial

"expiration_date: "2036-06-03T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The option vests in full on the earlier of the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/05/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fishman Mark

(Last)

(First)

(Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$29.55	06/03/2026		A		19,676		⁽¹⁾	06/03/2036	Common Stock	19,676	$0	19,676	D

Explanation of Responses:

1. The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

	By: /s/ Christine Bellon, Attorney-in-fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Beam Therapeutics (BEAM) director Mark Fishman report in this Form 4?

Mark Fishman reported receiving a compensatory stock option grant for 19,676 shares of Beam Therapeutics common stock. The award is a derivative security, giving him the right to buy shares later at a fixed exercise price of $29.55 per share.

Is the Beam Therapeutics (BEAM) Form 4 transaction a stock purchase or sale?

The Form 4 shows a stock option grant, not a share purchase or sale. Fishman acquired options at no cost, giving him the right to buy 19,676 Beam shares later at $29.55 per share if he chooses to exercise.

What are the key terms of Mark Fishman’s Beam Therapeutics (BEAM) option grant?

The grant covers 19,676 underlying Beam common shares at a $29.55 exercise price. The option vests fully on the earlier of one year from grant or just before the next annual shareholder meeting, and expires on June 3, 2036, if not exercised.

How does the Beam Therapeutics (BEAM) option granted to Mark Fishman vest?

The option vests in full once a time-based condition is met. Vesting occurs on the earlier of the first anniversary of the grant date or immediately before next year’s annual shareholder meeting, subject to his continued board service through that date.

How many Beam Therapeutics (BEAM) options does Mark Fishman hold after this filing?

Following this grant, the filing shows Fishman holding 19,676 stock options directly. Each option is exercisable into one share of Beam common stock at $29.55, providing potential equity exposure if he exercises in the future.

When do Mark Fishman’s Beam Therapeutics (BEAM) options expire?

The options are long-dated and expire on June 3, 2036, if not exercised. This extended term gives Fishman many years to decide whether to exercise, depending on his service on the board and Beam’s future share performance.